Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005951 · ClinicalTrials.gov registry record · Phase 1

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00005951 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Duke University. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005951, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.

Conditions Studied

Brain and Central Nervous System Tumors

Interventions

  • DRUG temozolomide
  • DRUG irinotecan hydrochloride

Study Locations (1)

North Carolina

  • Duke Comprehensive Cancer Center - Durham

Trial Details

FieldValue
Start Date 2000-08
Est. Completion 2006-04
Phase Phase 1

Sponsor

Duke University

1,725 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005951

The ClinicalTrials.gov registry entry for NCT00005951 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which temozolomide is the first listed.

NCT00005951 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00005951 about?

NCT00005951 is a clinical study titled "Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent p...

What is the current status of trial NCT00005951?

This trial is currently completed. It is a Phase 1 study. The study started on 2000-08. Estimated completion is 2006-04.

What conditions does trial NCT00005951 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00005951?

The interventions under investigation include: temozolomide (DRUG), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00005951?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005951 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Brain and Central Nervous System Tumors

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.